Heart Attack

Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea

ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways

Atherosclerosis, an inflammatory disease characterized by buildup of cholesterol, lipids, and other substances (plaque) in arteries leading to heart attack...

American Medical Association is Reviewing Cardio Diagnostics Holdings, Inc’s Integrated Epigenetic-Genetic Cardiovascular Medicine Tests for CPT PLA Codes

CPT codes are critical to receiving reimbursement from federal and private payersCHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader...

Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023

Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine

Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated...

As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)

Company Introduces Multimedia Resources to Bring Awareness of SADLAVAL, QC / ACCESSWIRE / November 8, 2023 / As daylight saving...

Family Medicine Specialists Selects Cardio Diagnostics’ Epigenetic-Genetic Tests for Assessing Heart Attack Risk for its BlueCross BlueShield Patients

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, and Family Medicine Specialists...

New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023

Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual...

Nanox.AI’s HealthCCSng AI Solution Reveals ~60% of Patients in Study had Previously Undetected Risk of a Cardiovascular Event from Routine Chest CTs

Beilinson Hospital in Israel used Nanox.AI’s HealthCCSng solution to conduct study on routine chest CT scans to assess impact of...

Cardio Diagnostics Holdings, Inc Partners with Ascension Borgess Hospital’s Heart Attack Prevention Clinic on Coronary Artery Disease Study

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a pioneer of artificial intelligence-driven precision cardiovascular medicine tests, today announced its AI-driven...

Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years

Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol...

EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA...

error: Content is protected !!